Am J Perinatol 2022; 39(09): 0995-1000
DOI: 10.1055/s-0040-1721374
Original Article

A Retrospective Analysis of the Effects of an Exclusively Human Milk Protein Diet on Neonatal Feeding Tolerance

Jessica Wickland
1   Division of Neonatal Perinatal Medicine, Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas
2   Division of Neonatology, Phoenix Children's Medical Group, Phoenix, Arizona
,
Christine Wade
3   Mednax Services Inc./Phoenix Perinatal Associates, Phoenix, Arizona
,
Becky Micetic
3   Mednax Services Inc./Phoenix Perinatal Associates, Phoenix, Arizona
,
Keith Meredith
3   Mednax Services Inc./Phoenix Perinatal Associates, Phoenix, Arizona
,
Gregory Martin
2   Division of Neonatology, Phoenix Children's Medical Group, Phoenix, Arizona
3   Mednax Services Inc./Phoenix Perinatal Associates, Phoenix, Arizona
› Author Affiliations
Zoom Image

Abstract

Objective This study was aimed to evaluate the effect of human milk protein fortifier (HMPF) versus bovine milk protein fortifier (BMPF) on feeding tolerance defined as the time to reach full feeds and necrotizing enterocolitis (NEC) in premature very low birth weight (VLBW) infants.

Study Design A retrospective review using the BabySteps Database included 493 infants born ≤33 weeks of gestational age and ≤1,250 g (g) birth weight. A total of 218 infants fed a human milk diet (HMD) with BMPF were compared with 275 infants fed an HMD with HMPF.

Results Full feeds were reached significantly sooner in the HMPF group (median: 14 vs. 16 days, p = 0.04). Weight at full feeds was significantly lower in the HMPF group (1,060 vs. 1110 g, p = 0.03).

Conclusion Using HMPF to provide an exclusively HMD allowed VLBW infants to achieve full feeds sooner, but did not affect rate of NEC compared with using a BMPF with an HMD.

Key Points

  • Human milk fortifiers with human milk are better than bovine human milk protein fortifiers.

  • Full feeds are reached sooner with a human milk protein fortifier.

  • The incidence of NEC did not change with the use of Prolacta.

Authors' Contributions

G.M., B.M., C.W., and J.W. conceptualized and designed the study. K.M. performed statistical analysis. G.M., B.M., C.W., and J.W. supervised the study. All authors drafted the manuscript and acquired, analyzed, or interpreted the data. They had full access to all the data in the study.




Publication History

Received: 18 June 2020

Accepted: 19 October 2020

Article published online:
29 November 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Crossref Cited-by logo
Article Citations